Published in
Elsevier, The Lancet Diabetes and Endocrinology, 9(9), p. 586-594, 2021
DOI: 10.1016/s2213-8587(21)00180-7
Links
Tools
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Journal article published in 2021 by
Mikhail N. Kosiborod,
Russell Esterline,
Remo H. M. Furtado,
Jan Oscarsson 
,
Samvel B. Gasparyan ,
Gary G. Koch,
Felipe Martinez,
Omar Mukhtar,
Subodh Verma,
Vijay Chopra,
Joan Buenconsejo,
Anna Maria Langkilde,
Philip Ambery,
Fengming Tang,
Kensey Gosch
and other authors.
,
Samvel B. Gasparyan ,
Gary G. Koch,
Felipe Martinez,
Omar Mukhtar,
Subodh Verma,
Vijay Chopra,
Joan Buenconsejo,
Anna Maria Langkilde,
Philip Ambery,
Fengming Tang,
Kensey Gosch
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 